Breaking News Instant updates and real-time market news.

2021-03-04 18:04:24 SWKS Skyworks $167.19 / -8.03 (-4.58%) 18:04 03/04/21 03/04 18:04 03/04/21 18:04	Skyworks downgraded to Neutral from Buy at Goldman Sachs Goldman Sachs analyst Toshiya Hari downgraded Skyworks to Neutral from Buy with a $135 price target. Hari downgraded the stock given limited upside potential to his unchanged price target. The analyst added that while he remains constructive on the company's long-term competitive position in the growing radio frequency market, he anticipates that the stock will perform largely in line with his broader semiconductor and semiconductor capital equipment coverage universe through the balance of the year.	11 Mar
SWKS Skyworks $167.19 / -8.03 (-4.58%) 02/16/21 Citi Citi opens positive catalyst watch on Lam, negative watch on Skyworks 02/10/21 B. Riley B. Riley Securities sees interesting opportunities in Skyworks, Silicon Motion 02/03/21 BMO Capital Qorvo price target raised to $190 from $135 at BMO Capital 02/02/21 Barclays Cirrus Logic upside from Apple 'falls a bit short,' says Barclays

2021-03-04 18:04:24

SWKS

Skyworks

$167.19 / -8.03 (-4.58%)

18:04

03/04/21

03/04

18:04

03/04/21

18:04

Skyworks downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs analyst Toshiya Hari downgraded Skyworks to Neutral from Buy with a $135 price target. Hari downgraded the stock given limited upside potential to his unchanged price target. The analyst added that while he remains constructive on the company's long-term competitive position in the growing radio frequency market, he anticipates that the stock will perform largely in line with his broader semiconductor and semiconductor capital equipment coverage universe through the balance of the year.

11
Mar

SWKS Skyworks

$167.19 / -8.03 (-4.58%)

02/16/21 Citi: Citi opens positive catalyst watch on Lam, negative watch on Skyworks

02/10/21 B. Riley: B. Riley Securities sees interesting opportunities in Skyworks, Silicon Motion

02/03/21 BMO Capital: Qorvo price target raised to $190 from $135 at BMO Capital

02/02/21 Barclays: Cirrus Logic upside from Apple 'falls a bit short,' says Barclays

TODAY'S FREE FLY STORIES

Conference/Events	Jefferies technology specialist to hold analyst/industry conference call » 07:55 04/12/21 04/12 07:55 04/12/21 07:55 Technology Specialist… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	iTeos Therapeutics to hold a conference call » 07:55 04/12/21 04/12 07:55 04/12/21 07:55 ITOS iTeos Therapeutics $26.99 / -3.12 (-10.36%) Management discusses… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events ITOS iTeos Therapeutics $26.99 / -3.12 (-10.36%) 04/11/21 iTeos announces preliminary data from ongoing Phase 1/2a trial of EOS-448 11/12/20 iTeos Therapeutics appoints Matthew Roden to board of directors ITOS iTeos Therapeutics $26.99 / -3.12 (-10.36%) 04/09/21 Piper Sandler AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler 04/05/21 Piper Sandler Piper Sandler continues to recommend iTeos Therapeutics into data 03/25/21 Wedbush iTeos Therapeutics price target raised to $52 from $46 at Wedbush 10/07/20 Baird iTeos Therapeutics initiated with an Outperform at Baird ITOS iTeos Therapeutics $26.99 / -3.12 (-10.36%) 03/24/21 iTeos Therapeutics reports Q4 EPS (43c), consensus (42c) 11/12/20 iTeos Therapeutics reports Q3 EPS (48c), consensus (36c) 24 Jul 08:00 Today iTeos Therapeutics - ITOS
Conference/Events	Blueprint Medicines to host conference call » 07:55 04/12/21 04/12 07:55 04/12/21 07:55 BPMC Blueprint Medicines $94.14 / +0.25 (+0.27%) Management reviews new… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events BPMC Blueprint Medicines $94.14 / +0.25 (+0.27%) 04/11/21 Blueprint presents data from registrational PATHFINDER trial of AYVAKIT 04/11/21 Blueprint presents preclinical data on broad precision therapy research pipeline 03/03/21 Blueprint Medicines: EMA validates Type II variation MAA for AYVAKYT 01/11/21 Blueprint says cash sufficient to achieve 'self-sustainable' profile BPMC Blueprint Medicines $94.14 / +0.25 (+0.27%) 04/09/21 Piper Sandler AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler 03/30/21 Credit Suisse Blueprint Medicines initiated with a Neutral at Credit Suisse 03/30/21 Credit Suisse Blueprint Medicines initiated with a Neutral at Credit Suisse 02/18/21 Barclays Blueprint Medicines price target raised to $95 from $90 at Barclays BPMC Blueprint Medicines $94.14 / +0.25 (+0.27%) 02/17/21 Blueprint Medicines reports Q4 EPS ($1.53), consensus ($1.62) 10/29/20 Blueprint Medicines reports Q3 EPS $11.16, consensus $7.72 08:00 Today Blueprint Medicines - BPMC 06/16/21 PDUFA Date for AYVAKIT
Downgrade	Yaskawa Electric downgraded to Hold from Buy at Jefferies » 07:54 04/12/21 04/12 07:54 04/12/21 07:54 YASKY Yaskawa Electric $107.20 / -0.89 (-0.82%) Jefferies analyst Sho… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research YASKY Yaskawa Electric $107.20 / -0.89 (-0.82%) 01/04/21 Goldman Sachs Yaskawa Electric upgraded to Buy from Neutral at Goldman Sachs 10/22/20 SMBC Nikko Yaskawa Electric upgraded to Neutral from Underperform at SMBC Nikko 07/21/20 Daiwa Yaskawa Electric downgraded to Neutral from Outperform at Daiwa
Hot Stocks	Alibaba affiliate Ant Group announces overhaul » 07:54 04/12/21 04/12 07:54 04/12/21 07:54 BABA Alibaba $223.35 / -4.9 (-2.15%) Alibaba affiliate Ant… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options BABA Alibaba $223.35 / -4.9 (-2.15%) 04/10/21 Alibaba fined $2.75B by China for antitrust, vows compliance 03/25/21 SEC begins implementing law that could delist foreign companies like Alibaba 02/16/21 Third Point buys Upstart, exits Caesars in Q4 02/03/21 Alibaba announces proposed offering of senior unsecured notes BABA Alibaba $223.35 / -4.9 (-2.15%) 07:37 Today Raymond James Alibaba price target lowered to $330 from $350 at Raymond James 06:41 Today Mizuho Alibaba antitrust ruling 'removes overhang,' says Mizuho 06:37 Today Citi Alibaba fine could help lift 'overhang' on shares, says Citi 06:36 Today KeyBanc Alibaba price target lowered to $305 from $315 at KeyBanc BABA Alibaba $223.35 / -4.9 (-2.15%) 02/02/21 Alibaba reports Q3 EPS $3.38, consensus $3.25 02/01/21 Notable companies reporting before tomorrow's open 02/01/21 Notable companies reporting before tomorrow's open 11/05/20 Alibaba reports Q2 adjusted EPS $2.65, consensus $2.11 BABA Alibaba $223.35 / -4.9 (-2.15%) 06:18 Today Tencent Music, Meituan concerned after Alibaba's $2.8B fine, FT reports 03/29/21 Energy Monster ownership dispute ahead of U.S. listing, Reuters reports 03/25/21 Ant Group to demand larger fees to rebuild valuation, FT reports 03/23/21 Tencent makes a push for growth, amid China push-back, Bloomberg says BABA Alibaba $223.35 / -4.9 (-2.15%) 03/07/21 Opening Day: InnovAge rises, Oscar Health slips on first trading day 02/28/21 Opening Day: Coinbase files to go public 02/21/21 Opening Day: Podcast app developer Auddia makes public debut 02/14/21 Opening Day: Bumble, Viant soar in market debuts BABA Alibaba $223.35 / -4.9 (-2.15%) 04/07/21 Unusually active option classes on open April 7th 03/10/21 Alibaba call buyer realizes 67% same-day gains 01/08/21 Notable open interest changes for January 8th 12/31/20 Notable open interest changes for December 31st

Upgrade	Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum » 07:52 04/12/21 04/12 07:52 04/12/21 07:52 EVLO Evelo Biosciences $10.03 / +0.005 (+0.05%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events Options EVLO Evelo Biosciences $10.03 / +0.005 (+0.05%) 03/23/21 Evelo Biosciences announces collaboration with Abdul Latif Jameel Health 03/09/21 Evelo Biosciences announces data from experimental model with EDP1815 03/09/21 Evelo Biosciences announces expected 2021 milestones 02/16/21 Evelo Biosciences appoints John Hohneker to board of directors EVLO Evelo Biosciences $10.03 / +0.005 (+0.05%) 04:50 Today Jefferies Evelo Biosciences upgraded to Buy from Hold at Jefferies 03/12/21 Chardan Evelo Biosciences price target raised to $15 from $10 at Chardan 01/25/21 JMP Securities Evelo Biosciences price target raised to $36 from $27 at JMP Securities 12/30/20 JMP Securities Evelo shares undervalued into atopic dermatitis data, says JMP Securities EVLO Evelo Biosciences $10.03 / +0.005 (+0.05%) 03/09/21 Evelo Biosciences reports Q4 EPS (62c), consensus (53c) 10/29/20 Evelo Biosciences reports Q3 EPS (45c), consensus (50c) 29 Jan 25 Jun 00:00 Today 20th Annual Virtual Healthcare Virtual Conference EVLO Evelo Biosciences $10.03 / +0.005 (+0.05%) 02/03/21 new option listings on February 3rd
Initiation	Duckhorn Portfolio initiated with a Buy at Jefferies » 07:48 04/12/21 04/12 07:48 04/12/21 07:48 NAPA Duckhorn Portfolio $18.89 / +0.785 (+4.34%) Jefferies analyst Kevin… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Syndicate On The Fly Options NAPA Duckhorn Portfolio $18.89 / +0.785 (+4.34%) 07:19 Today JPMorgan Duckhorn Portfolio initiated with an Overweight at JPMorgan 06:48 Today Citi Duckhorn Portfolio initiated with a Buy at Citi 06:44 Today Evercore ISI Duckhorn Portfolio initiated with an Outperform at Evercore ISI 06:24 Today Credit Suisse Duckhorn Portfolio initiated with an Outperform at Credit Suisse 18 Mar NAPA Duckhorn Portfolio $18.89 / +0.785 (+4.34%) 03/20/21 Opening Day: China's Tuya raised $915M in U.S. IPO NAPA Duckhorn Portfolio $18.89 / +0.785 (+4.34%) 04/07/21 new option listings and two option delistings on April 7th
Hot Stocks	Jazz Pharmaceuticals: FDA grants Priority Review of sNDA for Xywav » 07:48 04/12/21 04/12 07:48 04/12/21 07:48 JAZZ Jazz Pharmaceuticals $161.34 / +0.43 (+0.27%) Jazz Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events JAZZ Jazz Pharmaceuticals $161.34 / +0.43 (+0.27%) 04/01/21 Lava Therapeutics appoints Karen Wilson to board of directors 03/30/21 Jazz announces FDA approved revised label for Vyxeos 02/16/21 Jazz completes rolling submission for sNDA to FDA for Xywav oral solution 02/03/21 Jazz, GW Pharmaceuticals combo expected to accretive in first full year JAZZ Jazz Pharmaceuticals $161.34 / +0.43 (+0.27%) 04/06/21 RBC Capital Jazz Pharmaceuticals transferred with an Outperform at RBC Capital 04/01/21 Morgan Stanley Jazz Pharmaceuticals price target raised to $176 from $162 at Morgan Stanley 03/01/21 UBS Jazz Pharmaceuticals price target raised to $228 from $174 at UBS 02/24/21 Cowen Jazz Pharmaceuticals price target raised to $200 from $190 at Cowen JAZZ Jazz Pharmaceuticals $161.34 / +0.43 (+0.27%) 02/23/21 Jazz Pharmaceuticals sees FY21 adjusted EPS $15.65-$16.85, consensus $16.78 02/23/21 Jazz Pharmaceuticals reports Q4 EPS $4.00, consensus $4.20 02/16/21 GW Pharmaceuticals reports Q4 EPS (8c), consensus (60c) 11/02/20 Jazz Pharma narrows FY20 non-GAAP EPS view to $12.20-$13.00 from $11.90-$13.00 JAZZ Jazz Pharmaceuticals $161.34 / +0.43 (+0.27%) 04/05/21 'Failure is the new winning' for Jazz Pharmaceuticals, FFJ says JAZZ Jazz Pharmaceuticals $161.34 / +0.43 (+0.27%) 02/18/21 Rising High: An exclusive talk with multinational cannabis company Clever Leaves 02/11/21 Rising High: An exclusive talk with biotech company Enveric Biosciences 02/03/21 Fly Intel: Wall Street's top stories for Wednesday 02/03/21 Fly Intel: Wall Street's top stories at midday 05/24/21 Global Healthcare Virtual Conference 2021
Hot Stocks	Beyond Meat announces product distribution expansion with European retailers » 07:48 04/12/21 04/12 07:48 04/12/21 07:48 BYND Beyond Meat $130.24 / -4.45 (-3.30%) Beyond Meat announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options BYND Beyond Meat $130.24 / -4.45 (-3.30%) 04/08/21 Beyond Meat expands U.S. retail distribution within multiple grocery chains 04/07/21 Beyond Meat opens new manufacturing facility in JXEDZ near Shanghai 03/09/21 Walmart to expand Beyond Meat product offerings at stores 03/03/21 Peet's Coffee, Beyond Meat, JUST Egg launch 'Everything Plant-Based Sandwich' BYND Beyond Meat $130.24 / -4.45 (-3.30%) 04/07/21 Piper Sandler Piper Sandler survey shows more teens open to plant-based meat 04/05/21 JPMorgan BellRing, Hostess among JPMorgan's 'Own Now' names in food 03/19/21 Fly Intel: Top five analyst initiations 03/18/21 Stephens Stephens starts Beyond Meat at buy with alternative protein 'going mainstream' BYND Beyond Meat $130.24 / -4.45 (-3.30%) 02/25/21 Beyond Meat reports Q4 adjusted EPS (34c), consensus (13c) 02/25/21 Notable companies reporting after market close 11/09/20 Beyond Meat reports Q3 adj. EPS (28c), consensus 5c 11/09/20 Notable companies reporting after market close BYND Beyond Meat $130.24 / -4.45 (-3.30%) 04/08/21 Impossible Foods preparing for public listing, Reuters reports 04/08/21 Beyond Meat rival Impossible Foods prepping to come public, Reuters says 02/26/21 McDonald's clarifies to Bloomberg Beyond Meat's 'preferred supplier' status 02/04/21 Lawsuit challenging FDA approval of Impossible color additive, FSN reports BYND Beyond Meat $130.24 / -4.45 (-3.30%) 04/11/21 On the Fly: The Week in SPAC News 03/19/21 Molson Coors downgrade, Starbucks upgrade among today's top calls on Wall Street 03/02/21 Citi says buy Beyond Meat, has 'new-found enthusiasm' following partnerships 03/01/21 Fly Intel: After-Hours Movers BYND Beyond Meat $130.24 / -4.45 (-3.30%) 04/08/21 Unusually active option classes on open April 8th 04/07/21 Unusually active option classes on open April 7th 03/02/21 Unusually active option classes on open March 2nd 03/02/21 Largest borrow rate increases among liquid names
Earnings	InMode sees Q1 adjusted EPS 65c-67c, consensus 46c » 07:46 04/12/21 04/12 07:46 04/12/21 07:46 INMD InMode $80.64 / -0.19 (-0.24%) Sees Q1 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options INMD InMode $80.64 / -0.19 (-0.24%) 03/16/21 InMode files complaint against Cutera with the U.S. ITC 11/11/20 InMode granted U.S. patent for fractional radiofrequency technology Morpues8 INMD InMode $80.64 / -0.19 (-0.24%) 02/11/21 Baird InMode price target raised to $84 from $58 at Baird 02/11/21 Canaccord InMode price target raised to $80 from $69 at Canaccord 02/11/21 UBS InMode price target raised to $84 from $64 at UBS 10/21/20 Canaccord InMode price target raised to $51 from $42 at Canaccord INMD InMode $80.64 / -0.19 (-0.24%) 02/10/21 InMode sees 2021 non-GAAP EPS $2.34-$2.45, consensus $2.19 02/10/21 InMode reports Q4 non-GAAP EPS 94c, consensus 75c 01/12/21 InMode sees FY21 revenue $250M-$260M, consensus $245.08M 01/12/21 InMode sees FY20 non-GAAP EPS $2.08-$2.10, consensus $1.79 00:00 Today 20th Annual Virtual Healthcare Virtual Conference 05/24/21 Global Healthcare Virtual Conference 2021 INMD InMode $80.64 / -0.19 (-0.24%) 03/22/21 Largest borrow rate increases among liquid names 02/22/21 Largest borrow rate increases among liquid names 12/30/20 Largest borrow rate increases among liquid names 12/29/20 Largest borrow rate increases among liquid names

Hot Stocks	Centerra Gold to list common shares on NYSE » 07:45 04/12/21 04/12 07:45 04/12/21 07:45 CGAU Centerra Gold / + Centerra Gold is pleased… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Recommendations	PROG Holdings price target lowered to $58 from $65 at Truist » 07:45 04/12/21 04/12 07:45 04/12/21 07:45 PRG PROG Holdings $43.93 / +0.5 (+1.15%) Truist analyst Bill… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options PRG PROG Holdings $43.93 / +0.5 (+1.15%) 12/01/20 PROG Holdings begins operating as independent, publicly traded company PRG PROG Holdings $43.93 / +0.5 (+1.15%) 02/24/21 Stephens Aaron's peers also potentially received California inquiry, says Stephens 12/22/20 Raymond James Rent-A-Center price target raised to $45 from $38 at Raymond James 12/22/20 Stephens Rent-A-Center price target raised to $52 from $45 at Stephens 12/14/20 Berenberg Aaron's initiated with a Buy at Berenberg PRG PROG Holdings $43.93 / +0.5 (+1.15%) 02/25/21 PROG Holdings reports Q4 non-GAAP EPS 95c, consensus 90c 04/29/21 PROG Holdings - PRG PRG PROG Holdings $43.93 / +0.5 (+1.15%) 12/01/20 Two new option listings and two option delistings on December 1st
Hot Stocks	Cytokinetics announces preclinical data for CK-3773274 » 07:45 04/12/21 04/12 07:45 04/12/21 07:45 CYTK Cytokinetics $24.17 / +0.01 (+0.04%) Cytokinetics announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events Options CYTK Cytokinetics $24.17 / +0.01 (+0.04%) 02/18/21 Cytokinetics appoints Muna Bhanji to board of directors 01/13/21 Cytokinetics announces dosing of first patient in Cohort 2 of Redwood-HCM 01/11/21 Cytokinetics granted orphan drug designation for CK-3773274 in HCM 12/23/20 Cytokinetics regains European rights to omecamtiv mecarbil CYTK Cytokinetics $24.17 / +0.01 (+0.04%) 03/11/21 Wolfe Research Cytokinetics initiated with an Outperform at Wolfe Research 02/18/21 Barclays Cytokinetics initiated with an Overweight at Barclays 01/20/21 H.C. Wainwright Cytokinetics price target raised to $41 from $22 at H.C. Wainwright 12/28/20 Oppenheimer Amgen price target lowered to $266 from $274 at Oppenheimer CYTK Cytokinetics $24.17 / +0.01 (+0.04%) 11/04/20 Cytokinetics reports Q3 EPS (5c), consensus (34c) 17 Jul 00:00 Today 20th Annual Virtual Healthcare Virtual Conference 05/12/21 Cytokinetics Inc CYTK Cytokinetics $24.17 / +0.01 (+0.04%) 10/29/20 Cytokinetics call volume above normal and directionally bullish
Initiation	Vine Energy initiated with an Overweight at Morgan Stanley » 07:44 04/12/21 04/12 07:44 04/12/21 07:44 VEI Vine Energy $12.11 / +0.11 (+0.92%) Morgan Stanley analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Syndicate On The Fly VEI Vine Energy $12.11 / +0.11 (+0.92%) 06:50 Today Citi Vine Energy initiated with a Buy at Citi 06:22 Today Barclays Vine Energy initiated with an Equal Weight at Barclays 06:17 Today RBC Capital Vine Energy initiated with an Outperform at RBC Capital 06:16 Today BofA Vine Energy initiated with a Buy at BofA 18 Mar VEI Vine Energy $12.11 / +0.11 (+0.92%) 03/20/21 Opening Day: China's Tuya raised $915M in U.S. IPO
Hot Stocks	OpGen announces results from webinar on bacterial pneumonia co-infections » 07:42 04/12/21 04/12 07:42 04/12/21 07:42 OPGN OpGen $2.68 / -0.045 (-1.65%) OpGen announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly OPGN OpGen $2.68 / -0.045 (-1.65%) 03/08/21 OpGen announces publication of study results of Unyvero HPN panel 03/01/21 OpGen wins Chinese NMPA approval for Curetis Unyvero System 02/16/21 Ares Genetics announces publication of study on prediction of AST results 01/05/21 OpGen's Curetis, Annar enter Unyvero distribution partnership OPGN OpGen $2.68 / -0.045 (-1.65%) 03/02/21 Alliance Global Partners Alliance Global raises OpGen price target to $7, sees 'eventful 2021' 11/13/20 Alliance Global Partners OpGen price target raised to $5.65 from $5.00 at Alliance Global Partners 06/09/20 Alliance Global Partners Alliance Global Partners sees OpGen preliminary data as positive 06/03/20 Alliance Global Partners OpGen, NYS DOH collaboration extension 'highly positive,' says Alliance Global OPGN OpGen $2.68 / -0.045 (-1.65%) 01/13/21 OpGen reports preliminary 2020 revenue $5.2M, consensus $4.15M 01/13/21 OpGen reports preliminary Q4 revenue $1.3M, two est. $1.4M 10/15/20 OpGen reports preliminary Q3 revenue approx. $1M, one est. $1.6M OPGN OpGen $2.68 / -0.045 (-1.65%) 03/09/21 Second Sight, Auris Medical soar as 'meme stock' mania continues

Hot Stocks	Intellia Therapeutics appoints Georgia Keresty to board of directors » 07:41 04/12/21 04/12 07:41 04/12/21 07:41 NTLA Intellia Therapeutics $70.54 / -2.33 (-3.20%) , TAK Takeda Pharmaceutical $17.25 / +0.195 (+1.14%) , AZPN Aspen Technology $153.02 / -1.02 (-0.66%) , SLDB Solid Biosciences $5.20 / -0.17 (-3.17%) Intellia Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options NTLA TAK AZPN SLDB NTLA Intellia Therapeutics $70.54 / -2.33 (-3.20%) 03/30/21 Intellia Therapeutics treatment NTLA-2001 receives EU orphan drug designation 03/25/21 Intellia Therapeutics presents new data on expanded cell engineering 03/10/21 Intellia Therapeutics presents preclinical PoC for CRISPR-based in vivo editing 01/07/21 Intellia expects cash to fund requirements for at least next 24 months TAK Takeda Pharmaceutical $17.25 / +0.195 (+1.14%) 04/07/21 Kamada announces amendment to GLASSIA license agreement with Takeda 03/31/21 Takeda Pharmaceutical completes sale of OTC, non-core assets to Orifarm 03/30/21 Ovid Therapeutics, Takeda close agreement for commercialization of soticlestat 03/15/21 Takeda granted orphan status for pouchitis treatment vedolizumab AZPN Aspen Technology $153.02 / -1.02 (-0.66%) 03/17/21 L&T Technology Services and Aspen Technology team on engineering solutions 03/02/21 Aspen Technology appoints Chantelle Breithaupt CFO 03/02/21 Aspen Technology appoints Chantelle Breithaupt CFO 03/02/21 KVH Industries appoints Roger Kuebel as CFO SLDB Solid Biosciences $5.20 / -0.17 (-3.17%) 03/29/21 Suvretta Capital reports 5.13% passive stake in Solid Biosciences 03/15/21 Solid Biosciences reports interim functioning, biomarker data from IGNITE DMD 03/04/21 Solid Biosciences reports inducement grant to new CLO 03/04/21 Solid Biosciences names Erin Powers Brennan CLO, Joel Schneider COO NTLA TAK AZPN SLDB NTLA Intellia Therapeutics $70.54 / -2.33 (-3.20%) 03/04/21 JMP Securities Intellia Therapeutics initiated with an Outperform at JMP Securities 02/26/21 Truist Intellia Therapeutics price target raised to $80 from $40 at Truist 02/10/21 Chardan Intellia Therapeutics price target raised to $85 from $57.50 at Chardan 01/08/21 Barclays Intellia Therapeutics price target raised to $90 from $46 at Barclays TAK Takeda Pharmaceutical $17.25 / +0.195 (+1.14%) 04/05/21 Fly Intel: Top five analyst downgrades 04/05/21 Barclays Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays 04/05/21 Jefferies Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies 03/03/21 RBC Capital Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal AZPN Aspen Technology $153.02 / -1.02 (-0.66%) 02/16/21 KeyBanc Aspen Technology price target raised to $180 from $158 at KeyBanc 02/03/21 Baird Aspen Technology upgraded to Outperform from Neutral at Baird 01/05/21 Benchmark GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021 09/23/20 BofA Aspen Technology reinstated with a Neutral at BofA SLDB Solid Biosciences $5.20 / -0.17 (-3.17%) 03/16/21 Chardan Solid Biosciences price target raised to $20 from $12.50 at Chardan 03/16/21 Fly Intel: Top five analyst upgrades 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform at SVB Leerink 03/16/21 SVB Leerink Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink NTLA TAK AZPN SLDB NTLA Intellia Therapeutics $70.54 / -2.33 (-3.20%) 11/05/20 Intellia Therapeutics reports Q3 EPS (47c), consensus (59c) TAK Takeda Pharmaceutical $17.25 / +0.195 (+1.14%) 04/05/21 Molecular Templates to assume full rights of TAK-169 from Takeda AZPN Aspen Technology $153.02 / -1.02 (-0.66%) 01/27/21 Aspen Technology sees FY21 adjusted EPS $5.29-$5.58, consensus $5.00 01/27/21 Aspen Technology reports Q2 adjusted EPS $2.04, consensus $1.17 11/05/20 Aspen Technology backs FY21 adjusted EPS view $4.78-$5.32, consensus $5.01 SLDB Solid Biosciences $5.20 / -0.17 (-3.17%) 11/05/20 Solid Biosciences reports Q3 EPS (44c), consensus (34c) 19 Mar 02 Dec 03 Jun NTLA TAK SLDB NTLA Intellia Therapeutics $70.54 / -2.33 (-3.20%) 11/30/20 Fly Intel: After-Hours Movers TAK Takeda Pharmaceutical $17.25 / +0.195 (+1.14%) 03/03/21 Fly Intel: Wall Street's top stories for Wednesday 03/03/21 Fly Intel: Wall Street's top stories at midday 03/03/21 Fly Intel: Pre-market Movers SLDB Solid Biosciences $5.20 / -0.17 (-3.17%) 03/16/21 Fly Intel: Wall Street's top stories for Tuesday 03/16/21 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Wall Street's top stories at midday 12/11/20 Fly Intel: Pre-market Movers 05/24/21 Global Technology, Media & Communications Virtual Conference TAK TAK Takeda Pharmaceutical $17.25 / +0.195 (+1.14%) 04/06/21 Largest borrow rate increases among liquid names 04/05/21 Largest borrow rate increases among liquid names 03/19/21 Takeda Pharmaceutical call volume above normal and directionally bullish 03/17/21 Unusually active option classes on open March 17th
Hot Stocks	Platinum Equity to acquire Club Car from Ingersoll Rand for $1.7B » 07:40 04/12/21 04/12 07:40 04/12/21 07:40 IR Ingersoll-Rand $50.59 / +0.255 (+0.51%) Platinum Equity announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals Events IR Ingersoll-Rand $50.59 / +0.255 (+0.51%) 07:37 Today Ingersoll-Rand to sell specialty vehicle technologies segment to Platinum Equity 02/18/21 Ingersoll Rand selects Google Cloud to accelerate IoT innovation 02/16/21 AIP to acquire majority interest in Ingersoll-Rand's HPS segment 02/16/21 Ingersoll-Rand to sell majority interest in HPS to American Industrial Partners IR Ingersoll-Rand $50.59 / +0.255 (+0.51%) 04/06/21 Barclays Ingersoll-Rand price target raised to $56 from $53 at Barclays 02/24/21 Deutsche Bank Ingersoll-Rand price target raised to $50 from $47 at Deutsche Bank 02/16/21 UBS Ingersoll-Rand's deal to sell HPS interest 'positive,' says UBS 01/15/21 Jefferies Ingersoll-Rand price target raised to $53 from $45 at Jefferies IR Ingersoll-Rand $50.59 / +0.255 (+0.51%) 02/22/21 Ingersoll Rand sees FY21 revenue growth high-single to low-double digits 02/22/21 Ingersoll Rand reports Q4 adjusted EPS 53c, consensus 45c 02/22/21 Notable companies reporting after market close 11/02/20 Ingersoll-Rand reports Q3 adj. EPS 40c, consensus 31c 17 Jun IR Ingersoll-Rand $50.59 / +0.255 (+0.51%) 04/11/21 Ingersoll-Rand nearing $1.7B deal to sell golf cart business, Reuters reports 06/16/21 Ingersoll-Rand Inc
General news	Treasury Market Outlook: U.S. markets are little changed but still slightly underwater » 07:40 04/12/21 04/12 07:40 04/12/21 07:40 $ECON Economic Data / + Treasury Market Outlook:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><<
Recommendations	Southwest price target raised to $71 from $54 at Raymond James » 07:40 04/12/21 04/12 07:40 04/12/21 07:40 LUV Southwest $63.41 / -0.06 (-0.09%) Raymond James analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options LUV Southwest $63.41 / -0.06 (-0.09%) 04/05/21 CDC issues updated guidance on travel for fully vaccinated people 03/30/21 Southwest offers pre-cleared arrival into Hawaii 03/29/21 Southwest orders 100 Boeing 737 MAX jets, plus 155 options 03/29/21 Southwest adds 100 firm orders for Boeing 737 MAX 7 LUV Southwest $63.41 / -0.06 (-0.09%) 04/06/21 Morgan Stanley Southwest price target raised to $80 from $59 at Morgan Stanley 03/30/21 Jefferies Southwest price target raised to $70 from $55 at Jefferies 03/23/21 Fly Intel: Top five analyst upgrades 03/23/21 Argus Southwest upgraded to Buy from Hold at Argus LUV Southwest $63.41 / -0.06 (-0.09%) 01/28/21 Southwest reports Q4 ex-items EPS ($1.29), consensus ($1.68) 01/27/21 Notable companies reporting before tomorrow's open 01/27/21 Notable companies reporting before tomorrow's open 11/12/20 Southwest reports October operating revenue down about 65% year-over-year 29 Apr LUV Southwest $63.41 / -0.06 (-0.09%) 04/08/21 Southwest to bring back over 2,700 flight attendants for summer, Reuters says 03/31/21 Delta Air Lines to begin selling all seats on flights starting May 1, CNBC says 03/29/21 CDC chief warns of 'impending doom' amid rise in travel, AP reports 03/18/21 Biden administration looks to ease travel restrictions in mid-May, CNBC says LUV Southwest $63.41 / -0.06 (-0.09%) 03/29/21 Fly Intel: Wall Street's top stories for Monday 03/29/21 Fly Intel: Wall Street's top stories at midday 03/23/21 Netflix, Southwest upgrades among today's top calls on Wall Street 02/22/21 Airbnb, Snap upgrades among today's top calls on Wall Street LUV Southwest $63.41 / -0.06 (-0.09%) 03/08/21 Early notable gainers among liquid option names on March 8th 02/22/21 Southwest put volume heavy and directionally bearish 02/08/21 Southwest call volume above normal and directionally bullish 01/11/21 Unusually active option classes on open January 11th
Hot Stocks	Intra-Cellular announces presentation on PDE1 inhibitor program » 07:39 04/12/21 04/12 07:39 04/12/21 07:39 ITCI Intra-Cellular $31.68 / +0.17 (+0.54%) Intra-Cellular Therapies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate ITCI Intra-Cellular $31.68 / +0.17 (+0.54%) 02/24/21 Intra-Cellular introduces new molecular entity ITI-1284 02/22/21 Intra-Cellular applies for FDA approval of CAPLYTA 01/21/21 Intra-Cellular announce publication of results from CAPLYTA trial 12/29/20 Intra-Cellular announces initiation of clinical trials for ITI-LLAI ITCI Intra-Cellular $31.68 / +0.17 (+0.54%) 12/29/20 Cantor Fitzgerald Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald 12/15/20 Fly Intel: Top five analyst initiations 12/15/20 BofA Intra-Cellular initiated with a Buy at BofA 12/10/20 Fly Intel: Top five analyst initiations ITCI Intra-Cellular $31.68 / +0.17 (+0.54%) 02/25/21 Intra-Cellular reports Q4 EPS (76c), consensus (85c) 11/09/20 Intra-Cellular reports Q3 EPS (79c), consensus ($1.00) 11 Sep

Earnings	United Airlines sees Q1 revenue $3.2B, consensus $3.29B » 07:39 04/12/21 04/12 07:39 04/12/21 07:39 UAL United Airlines $58.43 / -0.99 (-1.67%) In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options UAL United Airlines $58.43 / -0.99 (-1.67%) 04/06/21 XpresSpa signs contract for XpresCheck COVID-19 facility at San Fransico Airport 04/06/21 United Airlines sets diversity goal for pilot training academy 04/05/21 United Airlines: Issue with website, app may prevent customers from purchases 04/05/21 CDC issues updated guidance on travel for fully vaccinated people UAL United Airlines $58.43 / -0.99 (-1.67%) 04/06/21 Fly Intel: Top five analyst upgrades 04/06/21 Morgan Stanley Morgan Stanley sees further airline upside, upgrades United and Alaska Air 04/06/21 Morgan Stanley United Airlines upgraded to Equal Weight from Underweight at Morgan Stanley 03/30/21 Jefferies United Airlines price target raised to $60 from $55 at Jefferies UAL United Airlines $58.43 / -0.99 (-1.67%) 01/20/21 United Airlines ended 2020 with $19.7B in available liquidity 01/20/21 United sees Q1 operating revenue down 65%-70%, consensus $4.06B 01/20/21 United Airlines reports Q4 adjusted EPS ($7.00), consensus ($6.60) 01/20/21 Notable companies reporting after market close 22 Apr UAL United Airlines $58.43 / -0.99 (-1.67%) 04/01/21 United Airlines to hire hundreds of pilots amid travel recovery, CNBC say 03/29/21 CDC chief warns of 'impending doom' amid rise in travel, AP reports 03/18/21 Biden administration looks to ease travel restrictions in mid-May, CNBC says 03/03/21 American, United to give J&J COVID-19 vaccine to Chicago workers, Reuters says UAL United Airlines $58.43 / -0.99 (-1.67%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 02/22/21 Airbnb, Snap upgrades among today's top calls on Wall Street 02/22/21 Fly Intel: Pre-market Movers 04/20/21 United Airlines - UAL UAL United Airlines $58.43 / -0.99 (-1.67%) 03/17/21 United Continental call volume above normal and directionally bullish 03/15/21 Early notable gainers among liquid option names on March 15th 03/03/21 United Continental call volume above normal and directionally bullish 02/25/21 Unusually active option classes on open February 25th
Recommendations	Mohawk Industries price target raised to $235 from $200 at Raymond James » 07:38 04/12/21 04/12 07:38 04/12/21 07:38 MHK Mohawk Industries $202.93 / +4.795 (+2.42%) Raymond James analyst Sam… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options MHK Mohawk Industries $202.93 / +4.795 (+2.42%) 03/08/21 Mohawk Industries Thiers sells almost $930K in company shares 02/12/21 Mohawk doesn't see commercial business rebounding to prior levels this year 02/12/21 Mohawk: Commercial business has improved from bottom, but remains depressed 02/10/21 Mohawk Industries names James F. Brunk CFO MHK Mohawk Industries $202.93 / +4.795 (+2.42%) 04/07/21 JPMorgan JPMorgan lays out long and short homebuilding ideas into earnings 03/17/21 Wolfe Research Mohawk Industries initiated with a Peer Perform at Wolfe Research 03/16/21 Wolfe Research Mohawk Industries initiated with a Peer Perform at Wolfe Research 02/18/21 Fly Intel: Top five analyst upgrades MHK Mohawk Industries $202.93 / +4.795 (+2.42%) 02/11/21 Mohawk Industries sees Q1 adjusted EPS $2.69-$2.79, consensus $2.11 02/11/21 Mohawk Industries reports Q4 adjusted EPS $3.54, consensus $2.87 10/29/20 Mohawk sees Q4 EPS $2.75-$2.87, consensus $1.99 10/29/20 Mohawk reports Q3 adjusted EPS $3.26, consensus $2.14 MHK Mohawk Industries $202.93 / +4.795 (+2.42%) 10/29/20 Fly Intel: After-Hours Movers 04/30/21 Mohawk Industries - MHK 05/20/21 Mohawk Industries, Inc. MHK Mohawk Industries $202.93 / +4.795 (+2.42%) 02/12/21 Early notable gainers among liquid option names on February 12th 11/02/20 Early notable gainers among liquid option names on November 2nd 10/30/20 Early notable gainers among liquid option names on October 30th
Recommendations	Medavail price target raised to $20 from $18 at Cowen » 07:38 04/12/21 04/12 07:38 04/12/21 07:38 MDVL Medavail $13.04 / -0.06 (-0.46%) Cowen analyst Charles… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research On The Fly MDVL Medavail $13.04 / -0.06 (-0.46%) 04/05/21 Cowen Medavail price target raised to $18 from $17 at Cowen 12/14/20 Lake Street Medavail initiated with a Buy at Lake Street 12/14/20 Cowen Medavail initiated with an Outperform at Cowen MDVL Medavail $13.04 / -0.06 (-0.46%) 12/21/20 Fly Insider: Net 1 UEPS, GrafTech among weeks notable insider trades
Hot Stocks	Watsco completes acquisition of Temperature Equipment Corporation » 07:38 04/12/21 04/12 07:38 04/12/21 07:38 WSO Watsco $276.17 / +5.22 (+1.93%) Watsco announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings WSO Watsco $276.17 / +5.22 (+1.93%) 04/01/21 Watsco board declares cash dividend of $1.95 03/16/21 Watsco to acquire Temperature Equipment Corporation, terms not disclosed 02/11/21 Watsco raises dividend 10% to $7.80 WSO Watsco $276.17 / +5.22 (+1.93%) 03/01/21 JPMorgan Watsco upgraded to Neutral from Underweight at JPMorgan 01/15/21 Jefferies Watsco price target raised to $250 from $230 at Jefferies 01/04/21 Vertical Research Watsco upgraded to Hold from Sell at Vertical Research 10/15/20 Stephens Watsco resumed with an Equal Weight at Stephens WSO Watsco $276.17 / +5.22 (+1.93%) 02/11/21 Watsco reports Q4 EPS $1.14, consensus 99c 12/30/20 Watsco reports 2020 annual sales surpass $5B 10/22/20 Watsco reports Q3 EPS $2.76, consensus $2.47
Hot Stocks	CVS Health expands access to COVID-19 vaccines in several states » 07:38 04/12/21 04/12 07:38 04/12/21 07:38 CVS CVS Health $74.03 / +0.25 (+0.34%) In an ongoing effort to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CVS CVS Health $74.03 / +0.25 (+0.34%) 04/05/21 CVS Health: COVID-19 antibody testing available at MinuteClinics across country 04/01/21 CVS Health surpasses 10M COVID-19 vaccine doses administered 03/29/21 CVS Health expands COVID-19 vaccinations in several states 03/16/21 Brookdale Senior Living completes second round of vaccine clinics at communities CVS CVS Health $74.03 / +0.25 (+0.34%) 04/08/21 Gordon Haskett Gordon Haskett highlights Encompass Health's 'interesting' Rhode Island trip 03/17/21 Guggenheim CVS Health downgraded to Neutral at Guggenheim after 34% rally 03/17/21 Fly Intel: Top five analyst downgrades 03/17/21 Guggenheim CVS Health downgraded to Neutral from Buy at Guggenheim CVS CVS Health $74.03 / +0.25 (+0.34%) 02/16/21 CVS Health sees FY21 revenue $276.1B-$280.6B, consensus $278.39B 02/16/21 CVS Health sees FY21 adjusted EPS $7.39-$7.55, consensus $7.54 02/16/21 CVS Health reports Q4 adjusted EPS $1.30, consensus $1.24 11/06/20 CVS Health raises FY20 adj. EPS view to $7.35-$7.45 from $7.14-$7.27 CVS CVS Health $74.03 / +0.25 (+0.34%) 03/23/21 CVS CEO not 'intimidated' by Amazon push into space, Fierce Healthcare says 03/02/21 IPG Mediabrands planning event focused on Black-owned media firms, AdAge says 02/14/21 Walmart COVID vaccine rollout heading to small towns, WSJ reports 02/11/21 CVS, Walmart to decide who gets leftover vaccine doses, WSJ reports CVS CVS Health $74.03 / +0.25 (+0.34%) 03/16/21 Fly Intel: Wall Street's top stories for Tuesday 03/16/21 Fly Intel: Wall Street's top stories at midday 03/16/21 Higher COVID vaccine reimbursement seen as 'windfall' for drug retailers 03/01/21 Ontrak plunges after announcing loss of Aetna contract 05/13/21 CVS Health Corp CVS CVS Health $74.03 / +0.25 (+0.34%) 03/29/21 CVS Health call volume above normal and directionally bullish 02/16/21 Unusually active option classes on open February 16th 01/11/21 CVS Health call volume above normal and directionally bullish 11/17/20 Unusually active option classes on open November 17th